Adaptive Signature Design- review of the biomarker guided adaptive phase –III controlled design

Genomics having a profound impact on oncology drug development necessitates the use of genomic signatures for therapeutic strategy and emerging medicine proposals. Since its advent in the arena of clinical trials biomarker-related predictive methods for the identification and selection of patient su...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhattacharyya, Arinjita, Rai, Shesh N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591770/
https://www.ncbi.nlm.nih.gov/pubmed/31289760
http://dx.doi.org/10.1016/j.conctc.2019.100378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591770/
https://www.ncbi.nlm.nih.gov/pubmed/31289760
http://dx.doi.org/10.1016/j.conctc.2019.100378

Ejemplares similares